The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Long-term follow-up from the UK Myeloma XI trial
Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone Medical Center, New York, NY, discusses the long-term follow-up of the UK Myeloma XI trial (NCT01554852). This is phase 3 trial had pathways for transplant eligible and transplant ineligible newly diagnosed multiple myeloma patients who, after immunomodulatory agent-based induction therapy +/- autologous stem cell transplant, were randomized between lenalidomide maintenance or observation. Results show lenalidomide maintenance prolongs progression-free survival and does not impact the aggressiveness of clinical relapse. Additionally, both induction and maintenance lenalidomide were associated with the best outcomes irrespective of cytogenetic risk group. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
